1st Cir. Upholds Award of Summary Judgment to GSK in Zofran Birth Defect MDL



DOCUMENTS
  • Opinion


BOSTON — The 1st Circuit U.S. Court of Appeals has upheld an award of summary judgment to GlaxoSmithKline LLC in the Zofran birth defect multidistrict litigation, ruling there was no “newly acquired evidence” that would have allowed GSK to add a stronger warning to the drug’s label via the Changes Being Effected process.

In a Jan. 9 opinion, the appellate panel found Japanese studies proffered by plaintiffs did not show a statistically significant relationship between Zofran and observed birth defects in animal subjects; therefore, the studies did not constitute “newly acquired evidence”.

Zofran is an FDA-approved prescription drug for the …

FIRM NAMES
  • Motley Rice LLC
  • Shook Hardy & Bacon LLP
  • Williams & Connolly LLP





UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Omni Tucson National Resort

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS